Pathways of Infusate Loss during Convection-Enhanced Delivery into the Putamen Nucleus

Quantifying Fluid Infusions and Tissue Expansion in Brain

(2011) M. Brady et al.   IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING

Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease

(2011) R Mark Richardson et al.   MOLECULAR THERAPY

Risk of surgical delivery to deep nuclei: A meta-analysis

(2011) Jonathan Kimmelman et al.   MOVEMENT DISORDERS

Intraoperative Intracerebral MRI-Guided Navigation for Accurate Targeting in Nonhuman Primates

(2010) Marina E. Emborg et al.   CELL TRANSPLANTATION

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

(2010) William J Marks et al.   LANCET NEUROLOGY

Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains

(2010) Raymond T. Bartus et al.   MOVEMENT DISORDERS

Poor drug distribution as a possible explanation for the results of the PRECISE trial

(2009) John H. Sampson et al.   JOURNAL OF NEUROSURGERY

Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF

(2009) M.E. Emborg et al.   NEUROBIOLOGY OF DISEASE

Striatal volume differences between non-human and human primates

(2008) Dali Yin et al.   JOURNAL OF NEUROSCIENCE METHODS

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

(2008) William J Marks et al.   LANCET NEUROLOGY